Abstract 2154P
Background
The role of lipid levels in the development and outcomes of cancer patients remains unclear in the literature. In this study, we aimed to analyze whether there is a relationship between total cholesterol levels and the survival of hospitalized cancer patients.
Methods
This retrospective observational study included patients admitted to the Medical Oncology Hospitalization Unit at La Paz University Hospital between September 2018 and January 2020. Total cholesterol levels, tumor type, treatment received, and mortality were analyzed.
Results
A total of 839 patients were included, with no differences in gender distribution. The most frequent tumor was lung (20.7%), followed by digestive tumors, including colorectal, esophagogastric, pancreatobiliary, or hepatic (33.4%), and breast (11.4%). The majority of patients were receiving active cancer-specific treatment, with chemotherapy (51.5%) or targeted treatments (18.6%) at the time of admission. At the end of the median follow-up period (31,8 months), 615 deaths had occurred (78.9%). The median overall survival (OS), regardless of tumor type, was 199 days. Having low total cholesterol values (less than 150 mg/dL) increased the risk of mortality by 25.9% compared to having physiological levels (150-200 mg/dL) (p=0.016, CI95% 1.045, 1.518)) with a Hazard Ratio of 1.259. Having high total cholesterol values (above 200 mg/dL) increased the risk of mortality by 30.6% compared to having physiological levels (p=0.036, CI95%(1.017, 1.677)) with an HR of 1.306.
Conclusions
To date, the majority of studies indicate that elevated cholesterol levels in patients with advanced cancer are associated with a higher risk of mortality, both due to a higher burden of comorbidity and the potential effects of cholesterol on oncogenic pathways. On the other hand, low cholesterol levels, possibly reflecting a significant metabolic dysregulation during cachexia, seem to be linked to a worse prognosis as well. Although the mechanisms by which high or low cholesterol levels increase the risk of mortality may differ, their incorporation into prognostic scores can contribute to a more accurate estimation of prognosis in advanced patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07
2193P - Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Presenter: Susana Cedres Perez
Session: Poster session 07